Augmented Anticancer Efficacy by si-RNA Complexed Drug-Loaded Mesoporous Silica Nanoparticles in Lung Cancer Therapy

Lung cancer remains the major cause of death throughout the world. However, with the cutting-edge therapeutic approaches the patient's survivability remains poor. Nanoparticle-mediated targeted gene therapy has surfaced globally for the therapeutic improvement in cancer patients. Recently, mesoporous silica nanoparticles (MSNs) have attracted much attention for the intracellular delivery of siRNA. Further codelivery strategy has been proposed to minimize the amount of each drug and to achieve the synergistic effect for cancer therapies. In the present investigation we explored the efficacy of codelivery of anticancer drugs along with survivin siRNA in the MSNs for a comparative therapeutic efficacy in lung cancer. Our results revealed such combinational approach has provoked enhanced therapeutic efficacy by synergistic drug activity while restraining the action of survivin protein. Thus, we anticipate this emerging approach may be quite beneficial for lung cancer therapy in future.